Institute for Molecular Medicine Finland

What Institute for Molecular Medicine Finland does

The Institute for Molecular Medicine Finland (FIMM) is a translational research institute operating within the Helsinki Institute of Life Science (HiLIFE) at the University of Helsinki, with a stated mission of bridging discovery research to clinical medicine. Founded in 2006 and headquartered at Fabianinkatu 33, Helsinki, FIMM employs between 51 and 100 staff and focuses on human genomics and precision medicine, addressing "Grand Challenges" intended to deliver direct health impact to the Finnish population. Its service portfolio comprises four pillars: FIMM Research Services (translational research and discovery-to-medicine expertise), FIMM Technology Resources (life science research infrastructures and technology platforms), FIMM Training Programs (training the next generation of molecular medicine scientists), and FIMM Partnerships (innovation and corporate collaboration for research translation).

FIMM's underlying technology base is centred on molecular medicine research infrastructure, with proprietary features not publicly itemised. Its distribution model is institutional rather than commercial: research outputs flow through academic collaborations, peer-reviewed publications, HiLIFE Life Science seminars, and direct engagement with the Finnish healthcare system. Marketing is similarly institutional, relying on scientific publications and seminar series rather than demand-generation channels.

The institute is embedded in a non-commercial operating model. Pricing is not applicable; research services are delivered through institutional collaborations and public funding routed via the University of Helsinki and HiLIFE. The ownership structure is academic: FIMM is a unit within a public Finnish university, with no disclosed venture capital, private equity, or external institutional investment. Johan Lundin is listed as Research Director. No revenue figure, funding rounds, acquisitions, patents, or M&A activity are disclosed in the available data, consistent with its status as a publicly funded research unit rather than a commercial enterprise.

Name

Institute for Molecular Medicine Finland

Legal name

Institute for Molecular Medicine Finland

Website

https://fimm.fi

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

The Institute for Molecular Medicine Finland (FIMM) is a translational research institute within the University of Helsinki's HiLIFE, conducting human genomics and precision medicine research and delivering clinical translation services to benefit the Finnish population.

Ownership category

akta.pro rank

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels1 record

Marketing channels2 records

Core offering

Institute for Molecular Medicine Finland (FIMM) is a translational research institute that conducts high-impact research in human genomics and precision medicine. It provides research services, life science technology platforms, training programs for scientists, and corporate/innovation collaboration programs aimed at translating molecular medicine discoveries into clinical applications. The institute operates as a unit within the Helsinki Institute of Life Science (HiLIFE) at the University of Helsinki, focusing on 'Grand Challenges' in molecular medicine to deliver health impact to the Finnish population.

Product overview

FIMM – Institute for Molecular Medicine Finland is a translational research institute operating as part of the Helsinki Institute of Life Science (HiLIFE) at the University of Helsinki. The institute offers an integrated portfolio of services centered on human genomics and precision medicine research. Its core offerings include FIMM Research Services (providing research infrastructure and expertise for discovery-to-medicine translation), FIMM Technology Resources (life science research infrastructures and technology platforms), FIMM Training Programs (training new generations of scientists), and FIMM Partnerships (innovation and corporate collaboration). The institute pursues 'Grand Challenges' in molecular medicine aimed at delivering direct health impact to the Finnish population.

Differentiator

Problem solved

Functional benefit

Products and services

• FIMM Research Services

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Helsinki Institute of Life Science (HiLIFE)coreStrategic or Co-development PartnerFIMM operates as a unit within HiLIFE at the University of Helsinki. HiLIFE serves as the parent institute providing strategic direction and cross-disciplinary collaboration opportunities across life science research units including Institute of Biotechnology, Neuroscience Center, and FIMM itself.
• University of HelsinkicoreStrategic or Co-development PartnerFIMM is a translational research institute as part of the University of Helsinki. The university provides institutional infrastructure, academic governance, and administrative support for FIMM's research activities in human genomics and precision medicine.

Recent moves5 records

Expansion highlights4 records

Direct peers

• Broad Institute of MIT and Harvard: Broad is a leading genomics and biomedical research institute affiliated with MIT and Harvard. It is directly comparable to FIMM in combining human genomics, translational research, training, and industry collaboration within an institute governance structure.
• European Molecular Biology Laboratory (EMBL): EMBL is the pan-European molecular life sciences research organization. FIMM is explicitly described as the "Nordic EMBL Partnership for Molecular Medicine," making EMBL its closest structural and scientific peer in mission, governance model, and research scope.
• Whitehead Institute for Biomedical Research: Whitehead is a MIT-affiliated biomedical research institute focused on molecular medicine and human disease. It mirrors FIMM's university-affiliated institute model, research excellence mandate, and translational orientation.
• Wellcome Sanger Institute: Sanger is a UK-based genomics and molecular medicine research institute with a translational mission. It shares FIMM's focus on human genomics, precision medicine, and large-cohort translational research delivered through an institute model rather than a university department.
• SciLifeLab: SciLifeLab is a Swedish national life science research infrastructure distributed across universities. It is a strong functional peer to FIMM, offering genomics and precision-medicine technology platforms, training, and industry collaboration services in a neighboring Nordic country.
• Icahn Institute for Genomics and Multiscale Biology: The Icahn Institute at Mount Sinai focuses on human genomics, systems biology, and precision medicine. It shares FIMM's translational genomics orientation and institute-within-university structure for advancing precision-medicine research.
• Max Planck Institute for Molecular Genetics: This Max Planck institute conducts research in molecular genetics and disease mechanisms. It is directly comparable to FIMM in its institute-based molecular medicine research model and emphasis on human disease genomics.

Regional players

• Karolinska Institutet: Karolinska is Sweden's leading medical university with extensive molecular medicine and precision medicine research. It is a regional peer to FIMM with comparable translational research, training, and clinical translation programs across the Nordics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• Xx.com/fimm_uh
• Facebookfacebook.com/146802245412437
• LinkedInlinkedin.com/company/uh-finland

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute for Molecular Medicine Finland